Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Treatment or prevention of hypokalemia in patients unable to take oral potassium,Maintenance of electrolyte balance in parenteral nutrition
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 m Eq/hour of potassium and a maximum concentration of 40 m Eq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 m Eq per day for mild depletion.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
Potassium has a complex disposition; the distribution between intracellular and extracellular compartments affects half-life. In normal renal function, the serum potassium half-life is approximately 4-6 hours after a dose, but this is not a true terminal half-life due to extensive tissue buffering. The body's total potassium turnover half-life is around 25-30 hours. In patients with renal impairment, half-life is prolonged proportionally to creatinine clearance.
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Potassium is primarily excreted unchanged by the kidneys; not metabolized. Dextrose is metabolized via glycolysis and oxidative phosphorylation.
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Potassium is primarily excreted renally (>90%) with about 10% excreted in feces via gastrointestinal secretion. Minimal excretion occurs through sweat. Renal handling involves glomerular filtration, proximal tubular reabsorption, and potassium secretion in the distal tubule and collecting duct regulated by aldosterone. Excretion is not linear and depends on potassium balance, renal function, and hormonal influences.
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
Potassium is not significantly bound to plasma proteins. Less than 2% of serum potassium is protein-bound; the remainder is free and ionized. There is no specific binding protein; any minimal binding is nonspecific to albumin and globulins.
Approximately 45-50% bound primarily to albumin.
Apparent volume of distribution (Vd) of potassium is large, approximately 0.5-0.6 L/kg for total body potassium, but this reflects distribution into total body water. Exchangeable potassium Vd is about 0.4 L/kg. The Vd for extracellular potassium is only about 0.05 L/kg. Clinically, Vd is not used for dosing because most potassium is intracellular; changes in serum concentration do not predict total body stores well.
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Intravenous: 100% bioavailability. Oral: Solid dosage forms have bioavailability >90% for immediate-release; enteric-coated formulations may have reduced bioavailability (70-80%) due to variability in dissolution and absorption. Liquid formulations approach 100% bioavailability. Absorption occurs throughout the small intestine via passive and active transport; bioavailability is affected by gastrointestinal motility and mucosal integrity.
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
GFR 10-50 m L/min: use with caution and reduce dose by 25-50%; monitor serum potassium closely. GFR <10 m L/min: avoid use unless severe hypokalemia with close monitoring; dose reduction of 50-75% recommended.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25% and monitor potassium. Child-Pugh C: reduce dose by 50% and monitor potassium carefully due to risk of hyperkalemia from decreased hepatic clearance.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
Intravenous infusion at 0.5-1 m Eq/kg/day of potassium, maximum concentration 40 m Eq/L, rate not exceeding 0.5-1 m Eq/kg/hour; adjust based on serum potassium and clinical response.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
Lower initial doses recommended (e.g., 10-20 m Eq/day) due to age-related decline in renal function; infuse at rate ≤5 m Eq/hour; monitor serum potassium and renal function closely.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
None
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Risk of hyperkalemia leading to cardiac arrhythmias, especially in patients with renal impairment or receiving potassium-sparing diuretics,Extravasation can cause tissue necrosis,Monitor serum potassium, glucose, and renal function,Use with caution in patients with heart disease or conditions predisposing to hyperkalemia,High concentration infusions require central line administration
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Concurrent use of potassium-sparing diuretics or ACE inhibitors without close monitoring,Conditions causing potassium retention (e.g., severe burns, Addison's disease),Hypersensitivity to potassium chloride or dextrose
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
Excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, tomatoes) may increase risk of hyperkalemia. Avoid potassium-containing salt substitutes. No specific food restrictions when used as directed, but dietary potassium should be considered in renally impaired patients.
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
Potassium chloride and dextrose are not teratogenic. Potassium is essential for fetal development; however, hyperkalemia or hypokalemia may cause fetal arrhythmias or growth restriction. Dextrose at 5% is non-teratogenic but maternal hyperglycemia may increase risk of fetal macrosomia or neonatal hypoglycemia.
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Potassium chloride and dextrose are normal blood constituents; breastfeeding is safe. M/P ratio not available; potassium levels in milk are regulated within normal range.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
Pregnancy increases plasma volume and GFR, reducing serum potassium slightly. No dose adjustment needed for potassium replacement if hypokalemia is corrected empirically. Dextrose 5% provides 5 g/100 m L; consider if maternal glucose intolerance or gestational diabetes present.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
This solution provides a low concentration of potassium (0.037% = 5 m Eq/L) in dextrose 5%. It is used for maintenance hydration and to prevent hypokalemia in patients with normal renal function. Avoid use in patients with severe renal impairment, hyperkalemia, or conditions causing potassium retention. Monitor serum potassium, glucose, and renal function during infusion. The low potassium concentration may not be sufficient for repletion in significant potassium deficits.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
This medication is given intravenously to maintain fluid and potassium levels. Report any discomfort, swelling, or redness at the IV site.,Avoid potassium-rich foods or supplements unless directed by your healthcare provider.,Tell your doctor if you have kidney problems, heart conditions, or if you are taking potassium-sparing diuretics or ACE inhibitors.,Inform your doctor if you experience muscle weakness, numbness, tingling, or irregular heartbeat.,Do not stop the infusion suddenly without medical advice.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 m Eq/hour of potassium and a maximum concentration of 40 m Eq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 m Eq per day for mild depletion.. The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic. Potassium is essential for fetal development; however, hyperkalemia or hypokalemia may cause fetal arrhythmias or growth restri. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.